OUR HIV MEDICINES
Our product portfolio consists of 17 prescription medicines, in the human immunodeficiency virus (HIV) space. These medicines may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries.
Please note that we are unable to provide detailed information about prescription medicines on this website in compliance with UK regulations.
You can find local information by clicking the button below and selecting your country of residence which will take you to your country specific website if available.
Healthcare Professionals
If you are a Healthcare Professional looking for information on ViiV Healthcare products, click the button below and select your country of residence.
▼Denotes that this medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please see the right hand tool bar for instructions on how to report a side effect.
Trademark |
International non-proprietary |
||
|---|---|---|---|
Trademark | Apretude | International non-proprietary | cabotegravir |
Trademark | Vocabria▼ |
International non-proprietary | cabotegravir |
Trademark | Rukobia▼ |
International non-proprietary | fostemsavir |
Trademark | Cabenuva | International non-proprietary | cabotegravir/rilpivirine |
Trademark | Dovato | International non-proprietary | dolutegravir/lamivudine |
Trademark | Juluca▼ | International non-proprietary | dolutegravir/rilpivirine |
Trademark | Triumeq | International non-proprietary | dolutegravir/ abacavir/ lamivudine |
Trademark | Tivicay | International non-proprietary | dolutegravir |
Trademark | Selzentry/ Celsentri | International non-proprietary | maraviroc |
Trademark | Epzicom/ Kivexa | International non-proprietary | abacavir/ lamivudine |
Trademark | Ziagen | International non-proprietary | abacavir |
Trademark | Trizivir | International non-proprietary | abacavir/ lamivudine/ zidovudine |
Trademark | Combivir | International non-proprietary | lamivudine/ zidovudine |
Trademark | Epivir | International non-proprietary | lamivudine |
Trademark | Retrovir | International non-proprietary | zidovudine |
Trademark | Lexiva/ Telzir | International non-proprietary | fosamprenavir |
Report a side effect
Our Privacy Notice outlines how ViiV Healthcare handles the processing of personal information when dealing with your enquiry, side effect or complaint.
Side effects should be reported to the Regulatory Authorities. If you are located in the UK, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ If you are located outside of the UK, please refer to your national reporting system.
Side effects should also be reported to ViiV Healthcare.
To report a side effect, please use the online reporting form below. This facility is provided by GSK, so you will be redirected to a GSK webpage.
NP-GBL-HVX-COCO-220021 October 2024.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
